Replies to post #109210 on Biotech Values

[jq1234]

In the best case for EXEL, XL184 will still be several years behind Denosumab, assuming both make it to market in the bone-met-prevention indication.

Don't think EXEL would be used for bone-mets-prevention, rather treat those who have developed bone mets already. Denosumab prevention is used when people don't currently have bone mets, even treatment with Denosumab or Zometa is as supportive care, not as cancer treatment.